fourth pfizer sars cov 2 booster dose Search Results


moderna sars cov 2 vaccination  (Moderna)
86
Moderna moderna sars cov 2 vaccination
Moderna Sars Cov 2 Vaccination, supplied by Moderna, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fourth+pfizer+sars+cov+2+booster+dose/10__4103_slash_ijot__ijot_124_23-107-18-18?v=Moderna
Average 86 stars, based on 1 article reviews
moderna sars cov 2 vaccination - by Bioz Stars, 2026-08
86/100 stars
  Buy from Supplier
moderna sars cov 2 mrna vaccination  (Moderna)
86
Moderna moderna sars cov 2 mrna vaccination
Moderna Sars Cov 2 Mrna Vaccination, supplied by Moderna, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fourth+pfizer+sars+cov+2+booster+dose/10__37349_slash_ei__2025__1003212-195-3-3?v=Moderna
Average 86 stars, based on 1 article reviews
moderna sars cov 2 mrna vaccination - by Bioz Stars, 2026-08
86/100 stars
  Buy from Supplier
mrna sars cov2 vaccines  (Pfizer Inc)
86
Pfizer Inc mrna sars cov2 vaccines
Mrna Sars Cov2 Vaccines, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fourth+pfizer+sars+cov+2+booster+dose/10__46883_slash_onc__2021__3504__0166-212-10-3?v=Pfizer+Inc
Average 86 stars, based on 1 article reviews
mrna sars cov2 vaccines - by Bioz Stars, 2026-08
86/100 stars
  Buy from Supplier
post sars cov 2 immunization  (Pfizer Inc)
86
Pfizer Inc post sars cov 2 immunization
Post Sars Cov 2 Immunization, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fourth+pfizer+sars+cov+2+booster+dose/pm37297989-8-28-30?v=Pfizer+Inc
Average 86 stars, based on 1 article reviews
post sars cov 2 immunization - by Bioz Stars, 2026-08
86/100 stars
  Buy from Supplier
resistant sars cov 2 against pf 07321332 nirmatrelvir  (Pfizer Inc)
86
Pfizer Inc resistant sars cov 2 against pf 07321332 nirmatrelvir
Resistant Sars Cov 2 Against Pf 07321332 Nirmatrelvir, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fourth+pfizer+sars+cov+2+booster+dose/fda_document____drugsatfda_docs_slash_nda_slash_2023_slash_217188orig1s000integratedr-4988-7-0?v=Pfizer+Inc
Average 86 stars, based on 1 article reviews
resistant sars cov 2 against pf 07321332 nirmatrelvir - by Bioz Stars, 2026-08
86/100 stars
  Buy from Supplier
pfizer-biontech sars-cov-2 vaccine  (BioNTech)
90
BioNTech pfizer-biontech sars-cov-2 vaccine
Time to presentation with thrombocytopenia following the most recent dose of a <t>SARS-CoV-2</t> vaccine. The graph compares vaccine type (Pfizer-BioNTech [n = 39] and Moderna [n = 37]) in persons without reported preexisting platelet disorders.
Pfizer Biontech Sars Cov 2 Vaccine, supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fourth+pfizer+sars+cov+2+booster+dose/pmc08483984-164-28-28?v=BioNTech
Average 90 stars, based on 1 article reviews
pfizer-biontech sars-cov-2 vaccine - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
sars-cov-2 bnt162b1  (BioNTech)
90
BioNTech sars-cov-2 bnt162b1
Time to presentation with thrombocytopenia following the most recent dose of a <t>SARS-CoV-2</t> vaccine. The graph compares vaccine type (Pfizer-BioNTech [n = 39] and Moderna [n = 37]) in persons without reported preexisting platelet disorders.
Sars Cov 2 Bnt162b1, supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fourth+pfizer+sars+cov+2+booster+dose/pmc08504644-104-16-18?v=BioNTech
Average 90 stars, based on 1 article reviews
sars-cov-2 bnt162b1 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
sars-cov-2 vaccine  (AstraZeneca ltd)
90
AstraZeneca ltd sars-cov-2 vaccine
A Total <t>anti-SARS-CoV-2</t> spike glycoprotein antibodies (Total GAM) and IgG and IgA anti SARS-CoV-2 spike glycoprotein antibodies measured at baseline, 3 months and 6 month follow up. At 6 months, only individuals who had not been vaccinated are shown. Data are provided as a ratio of the level of antibody compared to the cutoff calibrator set at 1.0. Percentage of individual above the assay cutoff at each time point is also provided above each column. Median and 95% confidence intervals are shown. B Receiver operator characteristic curve describing the relationship between baseline anti SARS-CoV-2 spike glycoprotein IgG ratio and binary IgG seropositivity at 6-month follow up. AUC = 0.80, p=0.01. C International reference materials NIBSC 20-136 (WHO) and 20-162 was run in triplicate serial dilutions and the IgG ratio determined. The minimum IgG ratio associated with guaranteed seropositivity 6 months from baseline is shown by the red and blue dotted lines. D Kinetics of total antibody response in 423 individuals following a single dose of the Pfizer-BioNTech vaccine. * demonstrate a significant difference (p<0.05) between the distributions of IgGAM ratios at each timepoint following vaccination between individuals who were seropositives and seronegative at baseline as determined by Kolmogorov-Smirnov test. Percentage of individual above the assay cutoff at each time point is also provided.
Sars Cov 2 Vaccine, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fourth+pfizer+sars+cov+2+booster+dose/med_rxiv__2021__02__24__21252368-75-9-11?v=AstraZeneca+ltd
Average 90 stars, based on 1 article reviews
sars-cov-2 vaccine - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
bivalent sars-cov-2 vaccine  (BioNTech)
90
BioNTech bivalent sars-cov-2 vaccine
A Total <t>anti-SARS-CoV-2</t> spike glycoprotein antibodies (Total GAM) and IgG and IgA anti SARS-CoV-2 spike glycoprotein antibodies measured at baseline, 3 months and 6 month follow up. At 6 months, only individuals who had not been vaccinated are shown. Data are provided as a ratio of the level of antibody compared to the cutoff calibrator set at 1.0. Percentage of individual above the assay cutoff at each time point is also provided above each column. Median and 95% confidence intervals are shown. B Receiver operator characteristic curve describing the relationship between baseline anti SARS-CoV-2 spike glycoprotein IgG ratio and binary IgG seropositivity at 6-month follow up. AUC = 0.80, p=0.01. C International reference materials NIBSC 20-136 (WHO) and 20-162 was run in triplicate serial dilutions and the IgG ratio determined. The minimum IgG ratio associated with guaranteed seropositivity 6 months from baseline is shown by the red and blue dotted lines. D Kinetics of total antibody response in 423 individuals following a single dose of the Pfizer-BioNTech vaccine. * demonstrate a significant difference (p<0.05) between the distributions of IgGAM ratios at each timepoint following vaccination between individuals who were seropositives and seronegative at baseline as determined by Kolmogorov-Smirnov test. Percentage of individual above the assay cutoff at each time point is also provided.
Bivalent Sars Cov 2 Vaccine, supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fourth+pfizer+sars+cov+2+booster+dose/pmc11125816-104-14-13?v=BioNTech
Average 90 stars, based on 1 article reviews
bivalent sars-cov-2 vaccine - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
targeted approach to specific sars-cov-2 variants  (BioNTech)
90
BioNTech targeted approach to specific sars-cov-2 variants
A Total <t>anti-SARS-CoV-2</t> spike glycoprotein antibodies (Total GAM) and IgG and IgA anti SARS-CoV-2 spike glycoprotein antibodies measured at baseline, 3 months and 6 month follow up. At 6 months, only individuals who had not been vaccinated are shown. Data are provided as a ratio of the level of antibody compared to the cutoff calibrator set at 1.0. Percentage of individual above the assay cutoff at each time point is also provided above each column. Median and 95% confidence intervals are shown. B Receiver operator characteristic curve describing the relationship between baseline anti SARS-CoV-2 spike glycoprotein IgG ratio and binary IgG seropositivity at 6-month follow up. AUC = 0.80, p=0.01. C International reference materials NIBSC 20-136 (WHO) and 20-162 was run in triplicate serial dilutions and the IgG ratio determined. The minimum IgG ratio associated with guaranteed seropositivity 6 months from baseline is shown by the red and blue dotted lines. D Kinetics of total antibody response in 423 individuals following a single dose of the Pfizer-BioNTech vaccine. * demonstrate a significant difference (p<0.05) between the distributions of IgGAM ratios at each timepoint following vaccination between individuals who were seropositives and seronegative at baseline as determined by Kolmogorov-Smirnov test. Percentage of individual above the assay cutoff at each time point is also provided.
Targeted Approach To Specific Sars Cov 2 Variants, supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fourth+pfizer+sars+cov+2+booster+dose/pmc12103547-112-6-1?v=BioNTech
Average 90 stars, based on 1 article reviews
targeted approach to specific sars-cov-2 variants - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
sars-cov-2 vaccine oxford/astrazeneca  (AstraZeneca ltd)
90
AstraZeneca ltd sars-cov-2 vaccine oxford/astrazeneca
A Total <t>anti-SARS-CoV-2</t> spike glycoprotein antibodies (Total GAM) and IgG and IgA anti SARS-CoV-2 spike glycoprotein antibodies measured at baseline, 3 months and 6 month follow up. At 6 months, only individuals who had not been vaccinated are shown. Data are provided as a ratio of the level of antibody compared to the cutoff calibrator set at 1.0. Percentage of individual above the assay cutoff at each time point is also provided above each column. Median and 95% confidence intervals are shown. B Receiver operator characteristic curve describing the relationship between baseline anti SARS-CoV-2 spike glycoprotein IgG ratio and binary IgG seropositivity at 6-month follow up. AUC = 0.80, p=0.01. C International reference materials NIBSC 20-136 (WHO) and 20-162 was run in triplicate serial dilutions and the IgG ratio determined. The minimum IgG ratio associated with guaranteed seropositivity 6 months from baseline is shown by the red and blue dotted lines. D Kinetics of total antibody response in 423 individuals following a single dose of the Pfizer-BioNTech vaccine. * demonstrate a significant difference (p<0.05) between the distributions of IgGAM ratios at each timepoint following vaccination between individuals who were seropositives and seronegative at baseline as determined by Kolmogorov-Smirnov test. Percentage of individual above the assay cutoff at each time point is also provided.
Sars Cov 2 Vaccine Oxford/Astrazeneca, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fourth+pfizer+sars+cov+2+booster+dose/pmc08461044-120-18-20?v=AstraZeneca+ltd
Average 90 stars, based on 1 article reviews
sars-cov-2 vaccine oxford/astrazeneca - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
sinopharm/sinovac-coronavac  (Sinopharm ltd)
90
Sinopharm ltd sinopharm/sinovac-coronavac
A Total <t>anti-SARS-CoV-2</t> spike glycoprotein antibodies (Total GAM) and IgG and IgA anti SARS-CoV-2 spike glycoprotein antibodies measured at baseline, 3 months and 6 month follow up. At 6 months, only individuals who had not been vaccinated are shown. Data are provided as a ratio of the level of antibody compared to the cutoff calibrator set at 1.0. Percentage of individual above the assay cutoff at each time point is also provided above each column. Median and 95% confidence intervals are shown. B Receiver operator characteristic curve describing the relationship between baseline anti SARS-CoV-2 spike glycoprotein IgG ratio and binary IgG seropositivity at 6-month follow up. AUC = 0.80, p=0.01. C International reference materials NIBSC 20-136 (WHO) and 20-162 was run in triplicate serial dilutions and the IgG ratio determined. The minimum IgG ratio associated with guaranteed seropositivity 6 months from baseline is shown by the red and blue dotted lines. D Kinetics of total antibody response in 423 individuals following a single dose of the Pfizer-BioNTech vaccine. * demonstrate a significant difference (p<0.05) between the distributions of IgGAM ratios at each timepoint following vaccination between individuals who were seropositives and seronegative at baseline as determined by Kolmogorov-Smirnov test. Percentage of individual above the assay cutoff at each time point is also provided.
Sinopharm/Sinovac Coronavac, supplied by Sinopharm ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fourth+pfizer+sars+cov+2+booster+dose/pmc11946420-178-12-21?v=Sinopharm+ltd
Average 90 stars, based on 1 article reviews
sinopharm/sinovac-coronavac - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

Image Search Results


Time to presentation with thrombocytopenia following the most recent dose of a SARS-CoV-2 vaccine. The graph compares vaccine type (Pfizer-BioNTech [n = 39] and Moderna [n = 37]) in persons without reported preexisting platelet disorders.

Journal: Blood

Article Title: SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP

doi: 10.1182/blood.2021013411

Figure Lengend Snippet: Time to presentation with thrombocytopenia following the most recent dose of a SARS-CoV-2 vaccine. The graph compares vaccine type (Pfizer-BioNTech [n = 39] and Moderna [n = 37]) in persons without reported preexisting platelet disorders.

Article Snippet: There was no significant difference in time to symptom onset ( ) or platelet count at presentation (data not shown) between those who received the Moderna vs the Pfizer-BioNTech SARS-CoV-2 vaccine.

Techniques:

Relative change in platelet counts pre– and post–SARS-CoV-2 vaccination in patients with preexisting ITP. (A) Relative change in platelet counts from pre-vaccination levels following doses 1 and 2 of a SARS-CoV-2 vaccine. (B) Effect of dose #2 in platelet count according to effect observed after dose 1.

Journal: Blood

Article Title: SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP

doi: 10.1182/blood.2021013411

Figure Lengend Snippet: Relative change in platelet counts pre– and post–SARS-CoV-2 vaccination in patients with preexisting ITP. (A) Relative change in platelet counts from pre-vaccination levels following doses 1 and 2 of a SARS-CoV-2 vaccine. (B) Effect of dose #2 in platelet count according to effect observed after dose 1.

Article Snippet: There was no significant difference in time to symptom onset ( ) or platelet count at presentation (data not shown) between those who received the Moderna vs the Pfizer-BioNTech SARS-CoV-2 vaccine.

Techniques:

A Total anti-SARS-CoV-2 spike glycoprotein antibodies (Total GAM) and IgG and IgA anti SARS-CoV-2 spike glycoprotein antibodies measured at baseline, 3 months and 6 month follow up. At 6 months, only individuals who had not been vaccinated are shown. Data are provided as a ratio of the level of antibody compared to the cutoff calibrator set at 1.0. Percentage of individual above the assay cutoff at each time point is also provided above each column. Median and 95% confidence intervals are shown. B Receiver operator characteristic curve describing the relationship between baseline anti SARS-CoV-2 spike glycoprotein IgG ratio and binary IgG seropositivity at 6-month follow up. AUC = 0.80, p=0.01. C International reference materials NIBSC 20-136 (WHO) and 20-162 was run in triplicate serial dilutions and the IgG ratio determined. The minimum IgG ratio associated with guaranteed seropositivity 6 months from baseline is shown by the red and blue dotted lines. D Kinetics of total antibody response in 423 individuals following a single dose of the Pfizer-BioNTech vaccine. * demonstrate a significant difference (p<0.05) between the distributions of IgGAM ratios at each timepoint following vaccination between individuals who were seropositives and seronegative at baseline as determined by Kolmogorov-Smirnov test. Percentage of individual above the assay cutoff at each time point is also provided.

Journal: medRxiv

Article Title: Longitudinal protection following natural SARS-CoV-2 infection and early vaccine responses: insights from a cohort of community based dental health care professionals

doi: 10.1101/2021.02.24.21252368

Figure Lengend Snippet: A Total anti-SARS-CoV-2 spike glycoprotein antibodies (Total GAM) and IgG and IgA anti SARS-CoV-2 spike glycoprotein antibodies measured at baseline, 3 months and 6 month follow up. At 6 months, only individuals who had not been vaccinated are shown. Data are provided as a ratio of the level of antibody compared to the cutoff calibrator set at 1.0. Percentage of individual above the assay cutoff at each time point is also provided above each column. Median and 95% confidence intervals are shown. B Receiver operator characteristic curve describing the relationship between baseline anti SARS-CoV-2 spike glycoprotein IgG ratio and binary IgG seropositivity at 6-month follow up. AUC = 0.80, p=0.01. C International reference materials NIBSC 20-136 (WHO) and 20-162 was run in triplicate serial dilutions and the IgG ratio determined. The minimum IgG ratio associated with guaranteed seropositivity 6 months from baseline is shown by the red and blue dotted lines. D Kinetics of total antibody response in 423 individuals following a single dose of the Pfizer-BioNTech vaccine. * demonstrate a significant difference (p<0.05) between the distributions of IgGAM ratios at each timepoint following vaccination between individuals who were seropositives and seronegative at baseline as determined by Kolmogorov-Smirnov test. Percentage of individual above the assay cutoff at each time point is also provided.

Article Snippet: 51.5% (n=450/873) had received a single dose of a SARS-CoV-2 vaccine (Oxford/AstraZeneca, n =17; Pfizer-BioNTech, n= 429; Unknown, n=4).

Techniques: